沙美特罗替卡松气雾剂联合异丙托溴铵对哮喘-慢性阻塞性肺疾病重叠综合征患者血清CRP、IgE和EOS水平的影响

Abstract
Figure/Table
References (15)
Related Citation (6)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the effect of Salmeterol and Fluticasone Propionate Aerosol and Ipratropium Bromide on serum C reactive protein(CRP),immunoglobulin E(IgE),the percentage of eosinophils(EOS)level in patients with asthma and chronic obstructive pulmonary disease overlap syndrome (ACOS).Methods A Total of 80 cases of ACOS patients who treated in our hospital from January 2016 to January 2018 were selected as subjects.According to the digital random method,they were randomly divided into control group and experimental group,with 40 cases in each group.The control group was treated with Salmeterol and Fluticasone Propionate Aerosol,and the experimental group was treated with Salmeterol and Fluticasone Propionate Aerosol combined with Ipratropium Bromide.The levels of serum CRP,IgE and EOS,the clinical efficacy and respiratory function improvement were observed and analyzed before and after treatment.Results The total effective rate of clinical treatment in the experimental group was significantly higher than that in the control group,and the difference was statistically significant(P＜0.05).The levels of serum CRP,IgE and EOS in the experimental group were significantly lower than those in the control group,the differences were statistically significant(P＜0.05).The one second forced breathing volume(FEV1),FEV1/forced vital capacity(FVC),predictive value of FEV1after treatment were significantly higher in the experimental group than those in the control group,the differences were statistically significant(P＜0.05).Conclusion In the treatment of ACOS patients,the treatment of Salmeterol and Fluticasone Propionate Aerosol combined with Ipratropium Bromide can achieve an ideal effect.It can significantly improve the level of serum CRP,IgE,EOS and pulmonary function,and is worthy of clinical promotion.

Key words： Salmeterol and Fluticasone Propionate Aerosol Isopatropium Bromide Asthma-chronic obstructive pulmonary disease overlap syndrome

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Wen-juan
	HUANG Li-nian
	WU Jing
	MENG Nan

Cite this article:

WANG Wen-juan,HUANG Li-nian,WU Jing, et al. Effect of Salmeterol and Fluticasone Propionate Aerosol combined with Ipratropium Bromide on serum levels of CRP,IgE and EOS in patients with asthma and chronic obstructive pulmonary disease overlap syndrome[J]. 中国当代医药, 2018, 25(27): 117-119.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I27/117

[1]	张海琴，程齐俭，万欢英.支气管哮喘-慢性阻塞性肺疾病重叠综合征的诊治进展[J].中国呼吸与危重监护杂志，2014，13（2）：219-222.
[2]	于仁志，韩磊，姜爱英，等.布地奈德福莫特罗治疗支气管哮喘-慢性阻塞性肺疾病重叠综合征43例疗效观察[J].中国药业，2017，26（21）：61-63.
[3]	王淑敏，马健，金亚明.射干麻黄汤加减联合信必可治疗哮喘-慢性阻塞性肺疾病重叠综合征急性发作期临床研究[J].南京中医药大学学报，2017，33（5）：535-537.
[4]	王俊敏.沙美特罗/替卡松联合噻托溴铵治疗哮喘-慢性阻塞性肺疾病重叠综合征的效果观察[J].中国乡村医药，2017，24（16）：31-32.
[5]	张瓒，黄天霞，于虹，等.支气管哮喘、慢性阻塞性肺疾病和支气管哮喘-慢性阻塞性肺疾病重叠综合征的临床和肺功能特点对比[J].广西医学，2017，39（8）：1262-1264.
[6]	李凤云，霍建民.哮喘-慢性阻塞性肺疾病重叠综合征的诊疗进展[J].临床肺科杂志，2017，22（8）：1508-1511.
[7]	诸军英，赵剑，陆俊俏，等.吸入糖皮质激素治疗对哮喘-慢性阻塞性肺疾病重叠综合征合并呼吸衰竭患者血清EOS、IL-6及CRP水平变化的研究[J].临床和实验医学杂志，2017，16（12）：1198-1201.
[8]	梁静波，方秋红.支气管哮喘-慢性阻塞性肺疾病重叠综合征的研究进展[J].中国老年学杂志，2017，37（7）：1784-1786.
[9]	游伟玲，李晓珍，张锋，等.沙美特罗/替卡松联合噻托溴铵吸入治疗哮喘-慢性阻塞性肺疾病重叠综合征的效果[J].中国乡村医药，2017，24（7）：17-18.
[10]	梁舜之，王沁，梁栋.哮喘-慢性阻塞性肺疾病重叠综合征的治疗体会[J].实用临床医药杂志，2016，20（24）：111-112.
[11]	崔佳玉，谢晓慧.新指南中支气管哮喘和慢性阻塞性肺疾病的药物治疗比较[J].中国医院药学杂志，2016，36（21）：1897-1900.
[12]	李芳，赵东东.支气管哮喘-慢性阻塞性肺疾病重叠综合征56例临床治疗体会[J].中国现代药物应用，2016，10（21）：100-101.
[13]	朱海玲，陈国忠，余红樱，等.哮喘-慢性阻塞性肺疾病重叠综合征患者呼出气一氧化氮检测的临床意义[J].武汉大学学报（医学版），2016，37（6）：938-941，945.
[14]	谭经福，叶永青，杨龙峰，等.噻托溴铵粉联合布地奈德福莫特罗吸入治疗支气管哮喘-慢性阻塞性肺疾病重叠综合征的短期疗效[J].临床荟萃，2016，31（8）：886-888， 892.
[15]	刘凌云，曾勉，左万里，等.哮喘-慢性阻塞性肺疾病重叠综合征患者氧化应激水平及抗氧化治疗效果的研究[J].中国医学创新，2016，13（21）：9-13.